OBJECTIVES: Coronary heart disease (CHD) is the second most important disease leading to mortalities in Hong Kong. In persons with established CHD, evidence has demonstrated that low-density lipoprotein (LDL) lowering therapy has resulted in reduced mortality and cardiovascular events. We evaluated the rate of LDL goal attainment of hyperlipidaemic patients at a public hospital in Hong Kong. METHODS: This is a prospective observational trial conducted at the Lipid Clinic of the Prince of Wales Hospital in Hong Kong. Chinese patients aged 18 years or above with history of hyperlipidaemia and CHD are included. Statin therapy must be prescribed for at least 3 months after initial hospitalization. Treatment patterns were determined by studying the dosages, titration, switch or discontinuation of statin therapy. A LDL level of 2.6 mmol/L was considered satisfactory. RESULTS: Thirty-nine patients were recruited. The mean age of patients was 61 ± 13 years old. Nearly 80% of patients had CHD risk factors and 40% of patients have CHD and CHD risk equivalents. In patients with comorbidities of hypertension and diabetes, nearly 50% and 60% of patients had unsatisfactory blood pressure control and unsatisfactory haemoglobin A1C levels respectively. The mean baseline LDL was 2.97 ± 0.99 mmol/L. Only 41% of patients were at LDL goal. Lipid lowering drugs used included rosuvastatin (21.4%), simvastatin (26.2%), atorvastatin (19.0%), fluvastatin (2.4%), ezetimibe (7.1%), cholestyramine (7.1%), gemfribrozil (2.4%) and acipimox (2.4%). Over 45% patients did not understand the purpose of their medications and possible side effects. CONCLUSION: The LDL goal attainment rate was relatively low in the present group of patients and there was room for improvement. The results of the current project paves way for the implementation of a clinical pharmacy service to assist in hyperlipidaemic management by providing drug education to patients and suggestions to physician in lipid lowering drug therapies.